Haas C D, Joseph U, Belt R J, Hoogstraten B
Cancer Treat Rep. 1981 May-Jun;65(5-6):439-41.
IMPY was given to 25 patients with advanced cancer on a twice weekly schedule in escalating doses from 165 to 3000 mg/m2. Nausea, vomiting, fatigue, generalized weakness, and decreases in performance status were dose-limiting. In one patient treated at a dose of 3000 mg/m2 for three doses, hemolytic anemia resulted, with a 6-g/dl decrease in hemoglobin. No tumor regression occurred. A reasonable starting dose for phase II studies is 1200 mg/m2 twice weekly for 3 weeks, with planned rapid escalation to 1800 mg/m2 in patients tolerating the lower dose level.
对25例晚期癌症患者给予IMP Y，每周两次，剂量从165mg/m²逐步递增至3000mg/m²。恶心、呕吐、疲劳、全身无力以及体能状态下降均为剂量限制性毒性。1例患者接受3000mg/m²剂量治疗3次后出现溶血性贫血，血红蛋白下降6g/dl。未观察到肿瘤消退。II期研究的合理起始剂量为每周两次，每次1200mg/m²，共3周，对于能耐受较低剂量水平的患者计划快速递增至1800mg/m²。
